# Filing Detail

Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001731122-24-000730
Filing Date
2024-05-06
Accepted
2024-05-06 06:01:40
Documents
7
Period of Report
2024-05-06

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | FORM DEF 14A | e5638_def14a.htm | DEF 14A | 571392
2 | GRAPHIC | image_001.jpg | GRAPHIC | 4198
3 | GRAPHIC | image_001.gif | GRAPHIC | 5620
4 | GRAPHIC | image_002.gif | GRAPHIC | 4943
5 | GRAPHIC | image_003.gif | GRAPHIC | 5180
6 | GRAPHIC | img_005.jpg | GRAPHIC | 434147
7 | GRAPHIC | img_006.jpg | GRAPHIC | 488007
| Complete submission text file | 0001731122-24-000730.txt |  | 1870710

Mailing Address 630 5TH AVENUE 20TH FLOOR NEW YORK NY 10111
Business Address 630 5TH AVENUE 20TH FLOOR NEW YORK NY 10111 844-689-3939
ANAVEX LIFE SCIENCES CORP. (Filer) CIK: 0001314052 (see all company filings)

EIN.: 980608404 | Fiscal Year End: 0930
Type: DEF 14A | Act: 34 | File No.: 001-37606 | Film No.: 24915384
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)